(RTTNews) - San Francisco-based digital therapeutics company, Better Therapeutics, Inc (BTTX) has submitted a de novo request for the marketing authorization of BT-001 to the US FDA. According to the company, it can be the first-in-class digital therapeutics to use cognitive behavioral therapy to treat Type 2 Diabetes patients.
Mark Berman, MD, Chief Medical Officer of the company, said, "Submitting this de novo request is not just a major milestone for our company but an important moment for patients, providers and payers. As the first digital therapeutic submitted to the FDA for the treatment of type 2 diabetes, BT-001 marks a new kind of treatment paradigm with the potential to address the root causes of this and other cardio-metabolic diseases."
Berman added that the treatment will help the patients move away from the traditional pharmaceutical treatment methods. Previously, Better also reported a sustainable and durable result of the pivotal trial of the medicine on a large control group.
If permitted, BT-001 will be the first prescription solution for CBT delivery to the patients suffering from Type 2 Diabetes through their own devices. The company is also looking at exploring options of treating cardiometabolic conditions like nonalcoholic fatty liver, hypertension, and hyperlipidemia through CBT.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
